Ibuprofen Za Otroke B. Braun (Ibuprofen)

The ibuprofen in this product works by non‑selectively inhibiting cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish inflammation, decrease pain signaling, and reset the hypothalamic temperature set‑point, resulting in analgesic, antipyretic, and anti‑inflammatory actions.

The dose of Ibuprofen Za Otroke B. Braun is determined by the prescribing clinician based on the child’s age, weight, clinical condition, and response to therapy. Healthcare professionals calculate the appropriate milligram per kilogram amount and adjust the infusion rate according to established hospital protocols.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use is generally avoided unless the potential benefit justifies the risk. Breastfeeding mothers should consult a healthcare provider, as ibuprofen can be excreted in milk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Compared with other pediatric NSAIDs, intravenous ibuprofen offers a rapid onset of action and the ability to achieve therapeutic plasma levels quickly, which can be advantageous in acute settings. Unlike acetaminophen, it also provides anti‑inflammatory effects, but it shares similar gastrointestinal and renal safety considerations as other NSAIDs.

Ibuprofen Za Otroke B. Braun must be stored at 2‑8 °C. Keep the vials refrigerated, protect them from light, and avoid freezing or shaking the solution. Before administration, allow the product to reach room temperature if required by the hospital protocol, and inspect for particulate matter or discoloration.

The product is administered intravenously by a qualified healthcare professional. It is typically diluted in an appropriate compatible IV fluid and infused over a prescribed period, often 15‑30 minutes, depending on the clinical situation and the patient’s tolerance.

Serious risks include acute kidney injury, gastrointestinal bleeding or ulceration, severe hypersensitivity reactions such as anaphylaxis, and rare hepatotoxicity. Patients with pre‑existing renal, hepatic, or cardiovascular disease should be monitored closely, and any signs of severe adverse reactions require immediate medical attention.

Children with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal bleeding or ulcer disease, severe renal or hepatic impairment, and patients receiving anticoagulant therapy with uncontrolled bleeding risk should not receive this product. Clinical judgment is essential for each individual case.